CT
MRNA icon

Caldwell Trust’s Moderna MRNA Stock Holding History

Caldwell Trust’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-100
Closed -$5.08K – 836
2026
Q1 		$5.08K Buy
+100
New +$4.67K ﹤0.01% 710
2024
Q4 		– Sell
-137
Closed -$9.16K – 723
2024
Q3 		$9.16K Hold
137
– – ﹤0.01% 615
2024
Q2 		$16.3K Hold
137
– – ﹤0.01% 570
2024
Q1 		$14.6K Hold
137
– – ﹤0.01% 588
2023
Q4 		$13.6K Sell
137
-272
-67% -$22.9K ﹤0.01% 586
2023
Q3 		$42.2K Buy
409
+65
+19% +$7.25K 0.01% 464
2023
Q2 		$41.8K Buy
344
+62
+22% +$8.27K 0.01% 475
2023
Q1 		$43.3K Buy
282
+80
+40% +$13.2K 0.01% 459
2022
Q4 		$36.3K Buy
202
+137
+211% +$22.4K 0.01% 470
2022
Q3 		$7.69K Hold
65
– – ﹤0.01% 634
2022
Q2 		$9.29K Hold
65
– – ﹤0.01% 632
2022
Q1 		$11.2K Hold
65
– – ﹤0.01% 633
2021
Q4 		$16.5K Hold
65
– – ﹤0.01% 587
2021
Q3 		$25K Hold
65
– – ﹤0.01% 534
2021
Q2 		$15.3K Hold
65
– – ﹤0.01% 601
2021
Q1 		$8.51K Hold
65
– – ﹤0.01% 645
2020
Q4 		$6.79K Buy
+65
New +$6.58K ﹤0.01% 649

Other funds holding MRNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return

Caldwell Trust's MRNA Position: Q2 2026 in Review

Caldwell Trust sold out of Moderna (MRNA) in Q2 2026, closing a stake of 100 shares — an estimated $5.08K sold.

Caldwell Trust first reported a position in MRNA in Q4 2020 and held it in 17 quarters. The position peaked at $43.3K in Q1 2023. 780 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

  • Caldwell Trust reported no remaining Moderna position as of Q2 2026 after selling out during the quarter.
  • Caldwell Trust sold 100 Moderna shares in Q2 2026, an estimated $5.08K.
  • Caldwell Trust first reported a position in Moderna in Q4 2020 and held it in 17 quarters.
  • Caldwell Trust's Moderna position peaked at $43.3K in Q1 2023.
  • 780 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on Caldwell Trust's 13F filing for Q2 2026, filed 3 Aug 2026.